Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.45 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CFTR | P13569 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | SLC5A2 | P31639 | 4/20 | 0.35 |
| ▸ | ATP1A1 | P05023 | 1/20 | 0.34 |
| ▸ | ATP1B1 | P05026 | 1/20 | 0.34 |
| ▸ | ATP1A3 | P13637 | 1/20 | 0.34 |
| ▸ | ATP1B2 | P14415 | 1/20 | 0.34 |
| ▸ | ATP1A2 | P50993 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29865963 | 0.86 | DRD2 (0.47) | DRD2DRD3CHRNB4CHRNA3HDAC4 | |
| SCHEMBL23647871 | 0.86 | DRD2 (0.47) | DRD2DRD3CHRNB4CHRNA3HDAC4 | |
| SCHEMBL1810639 | 0.86 | TDP1 (0.41) | DRD2DRD3CHRNB4CHRNA3HDAC4 | |
| SCHEMBL16957589 | 0.82 | DRD2 (0.55) | DRD2DRD3CHRNB4CHRNA3HDAC4 | |
| SCHEMBL15349884 | 0.82 | DRD2 (0.49) | DRD2DRD3CHRNB4CHRNA3HDAC4 | |
| SCHEMBL25369976 | 0.81 | NCF1 (0.44) | HDAC4MEF2DENPP2CYP3A4 | |
| SCHEMBL30580164 | 0.81 | NCF1 (0.44) | HDAC4MEF2DENPP2CYP3A4 | |
| SCHEMBL23712321 | 0.81 | DRD2 (0.48) | DRD2DRD3CHRNB4CHRNA3HDAC4 | |
| SCHEMBL7257300 | 0.79 | DRD2 (0.60) | DRD2DRD3CHRNB4CHRNA3HDAC4 | |
| SCHEMBL7258234 | 0.79 | DRD2 (0.60) | DRD2DRD3CHRNB4CHRNA3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692085-A2 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | Nxera Pharma UK Limited (GB) | 2026-02-11 | — | — | EP | disclosed |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-4041388-B1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2025-11-26 | — | — | EP | disclosed |
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | Nxera Pharma UK Limitied (GB) | 2025-08-19 | — | — | US | disclosed |
| CN-119256054-A | Ultraviolet curable ink, method for forming cured product, and device for forming cured product | 柯尼卡美能达株式会社 | 2025-01-03 | — | — | CN | disclosed |
| CN-114585603-B | Prostaglandin EP4Receptor antagonist compounds | 奈克斯拉制药英国有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118742619-A | Adhesive composition, adhesive film for circuit connection, and method for producing connection structure | 株式会社力森诺科 | 2024-10-01 | — | — | CN | disclosed |
| CN-118715300-A | Adhesive composition, adhesive film for circuit connection, and method for producing connection structure | 株式会社力森诺科 | 2024-09-27 | — | — | CN | disclosed |
| CN-118685077-A | Method for forming nonaqueous inkjet ink and cured product | 柯尼卡美能达株式会社 | 2024-09-24 | — | — | CN | disclosed |
| CN-118556302-A | Inkjet ink for forming barrier ribs, inkjet ink set for forming barrier ribs, method for manufacturing LED device, and LED device | 柯尼卡美能达株式会社 | 2024-08-27 | — | — | CN | disclosed |
| WO-2021069927-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | HEPTARES THERAPEUTICS LIMITED (GB) | 2021-04-15 | — | — | WO | disclosed |
| WO-2020162552-A1 | INKJET INK FOR COLOR FILTER, PHOTOCONVERSION LAYER, AND COLOR FILTER | DIC株式会社 | 2020-08-13 | — | — | WO | disclosed |
| US-10323028-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-06-18 | — | — | US | disclosed |
| US-10323028-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | ASTRAZENECA AB (SE) | 2019-06-18 | — | — | US | disclosed |
| EP-3383873-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2018-10-10 | — | — | EP | disclosed |
| WO-2017093299-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017093299-A1 | 1,3,4-THIADIAZOLE COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2017-06-08 | — | — | WO | disclosed |
| US-20170152255-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152255-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
| US-20170152255-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | ASTRAZENECA AB (SE) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12391641-B2 | Prostaglandin EP4 receptor antagonist compounds | PTGER1, PTGER4, PTGER2 | DRD2 1091/4885DRD3 1063/4885CHRNB4 657/4885 |
| US-20170152255-A1 | 1,3,4-Thiadiazole Compounds and Their Use in Treating Cancer | GLS2, GLS, GLUL | DRD2 1875/4885DRD3 1542/4885CHRNB4 4728/4885 |
| US-10323028-B2 | 1,3,4-thiadiazole compounds and their use in treating cancer | GLS2, GLS, GLUL | DRD2 1875/4885DRD3 1542/4885CHRNB4 4728/4885 |
| US-20260015314-A1 | PROSTAGLANDIN EP4 RECEPTOR ANTAGONIST COMPOUNDS | PTGER4, PTGER1, PTGER3 | DRD2 1010/4885DRD3 1400/4885CHRNB4 346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.